Fu Xiao - Concord Medical Chief Operating Officer

CCM Stock  USD 5.02  0.12  2.45%   

COO

Ms. Xiao Fu is Chief Operating Officer of the company. Ms.Xiao Fuhas served as a Senior Vice President of the Company sinceJuly 2009. Ms.Xiao Fujoined China Medstar in 1997 and served as its Senior Vice President prior to Concord Medical acquisition of China Medstar. Prior to joining China Medstar, Ms.Xiao Fuserved as a Sales Supervisor of RhonePoulenc Rorer from 1995 toDecember 1997. Ms.Xiao Fugraduated from the Shanghai Second Military Medical University in 1986, majoring in Healthcare. since 2019.
Age 53
Tenure 5 years
Address East Zone, Hanwei Plaza, Beijing, China, 100020
Phone86 10 5903 6688
Webhttps://www.concordmedical.com

Concord Medical Management Efficiency

The company has Return on Asset of (0.044) % which means that on every $100 spent on assets, it lost $0.044. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.324) %, meaning that it generated no profit with money invested by stockholders. Concord Medical's management efficiency ratios could be used to measure how well Concord Medical manages its routine affairs as well as how well it operates its assets and liabilities. As of the 29th of December 2024, Return On Tangible Assets is likely to drop to -0.06. In addition to that, Return On Capital Employed is likely to grow to -0.11. At this time, Concord Medical's Other Current Assets are very stable compared to the past year. As of the 29th of December 2024, Intangible Assets is likely to grow to about 435.8 M, while Other Assets are likely to drop about 26.2 M.
Concord Medical Services has 3.3 B in debt with debt to equity (D/E) ratio of 1.25, which is OK given its current industry classification. Concord Medical Services has a current ratio of 0.7, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Note however, debt could still be an excellent tool for Concord to invest in growth at high rates of return.

Similar Executives

Found 1 records

COO Age

Barry PortThe Ensign Group
50
Concord Medical Services Holdings Limited, together its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the Peoples Republic of China. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, the Peoples Republic of China. Concord Medical operates under Medical Care Facilities classification in the United States and is traded on New York Stock Exchange. It employs 972 people. Concord Medical Services (CCM) is traded on New York Stock Exchange in USA. It is located in East Zone, Hanwei Plaza, Beijing, China, 100020 and employs 727 people. Concord Medical is listed under Health Care Providers & Services category by Fama And French industry classification.

Management Performance

Concord Medical Services Leadership Team

Elected by the shareholders, the Concord Medical's board of directors comprises two types of representatives: Concord Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Concord. The board's role is to monitor Concord Medical's management team and ensure that shareholders' interests are well served. Concord Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Concord Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Xun Liu, Financial Controller
Zheng Cheng, President, Director and Member of Investment Committee
Qing Pan, Director
Matthew Callister, Chief Medical Officer
Fu Xiao, Chief Operating Officer
Jianyu Yang, Chairman, CEO, Chairman of Compensation Committee and Member of Investment Committee
Boxun Zhang, Independent Director
Yaw Yap, CFO and Member of Investment Committee
Ting Lee, Independent Non-Executive Director
Weibo Yin, Independent Director and Member of Audit Committee
Liping Zhang, Independent Director
Yue Yu, Director

Concord Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Concord Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Concord Medical Services is a strong investment it is important to analyze Concord Medical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Concord Medical's future performance. For an informed investment choice regarding Concord Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Concord Medical Services. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Concord Medical. If investors know Concord will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Concord Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(11.88)
Revenue Per Share
107.978
Quarterly Revenue Growth
(0.23)
Return On Assets
(0.04)
Return On Equity
(0.32)
The market value of Concord Medical Services is measured differently than its book value, which is the value of Concord that is recorded on the company's balance sheet. Investors also form their own opinion of Concord Medical's value that differs from its market value or its book value, called intrinsic value, which is Concord Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Concord Medical's market value can be influenced by many factors that don't directly affect Concord Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Concord Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Concord Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Concord Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.